LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 358

Search options

  1. Book ; Thesis: Wybrane aspekty dziedzicznej predyspozycji do raka gruczołu krokowego i nowotworów innych narządów

    Cybulski, Cezary

    = Selected aspects of inherited susceptibility to prostate cancer and tumors of different site of origin

    (Annales Academiae Medicae Stetinensis : Suplement ; 114)

    2007  

    Title variant Selected aspects of inherited susceptibility to prostate cancer and tumors of different site of origin
    Author's details Cezary Cybulski
    Series title Annales Academiae Medicae Stetinensis : Suplement ; 114
    Annales Academiae Medicae Stetinensis
    Annales Academiae Medicae Stetinensis ; Suplement
    Collection Annales Academiae Medicae Stetinensis
    Annales Academiae Medicae Stetinensis ; Suplement
    Language Polish ; English
    Size 102 S. : graph. Darst.
    Publisher Pomorska Akademia Medyczna
    Publishing place Szczecin
    Publishing country Poland
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Szczecin, Habil.-Schr
    HBZ-ID HT015547480
    ISBN 978-83-89318-75-6 ; 83-89318-75-X
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs B 895 -Supl.114- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.

    Szczepanek, Joanna / Skorupa, Monika / Jarkiewicz-Tretyn, Joanna / Cybulski, Cezary / Tretyn, Andrzej

    International journal of molecular sciences

    2023  Volume 24, Issue 8

    Abstract: Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as ... ...

    Abstract Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modifying enzymes, and mRNA regulators (such as miRNA mimics and antagomiRs) can reverse these alterations. Therefore, these epigenetic-targeting drugs are promising candidates for cancer treatment. However, there is currently no effective epi-drug monotherapy for breast cancer. Combining epigenetic drugs with conventional therapies has yielded positive outcomes and may be a promising strategy for breast cancer therapy. DNA methyltransferase inhibitors, such as azacitidine, and histone deacetylase inhibitors, such as vorinostat, have been used in combination with chemotherapy to treat breast cancer. miRNA regulators, such as miRNA mimics and antagomiRs, can alter the expression of specific genes involved in cancer development. miRNA mimics, such as miR-34, have been used to inhibit tumor growth, while antagomiRs, such as anti-miR-10b, have been used to inhibit metastasis. The development of epi-drugs that target specific epigenetic changes may lead to more effective monotherapy options in the future.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; DNA Methylation ; MicroRNAs/metabolism ; Histone Code ; Antagomirs/metabolism ; Epigenesis, Genetic ; Histone Deacetylase Inhibitors/pharmacology ; Histone Deacetylase Inhibitors/therapeutic use ; Methyltransferases/metabolism ; DNA/metabolism
    Chemical Substances MicroRNAs ; Antagomirs ; Histone Deacetylase Inhibitors ; Methyltransferases (EC 2.1.1.-) ; DNA (9007-49-2)
    Language English
    Publishing date 2023-04-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24087235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Nuclear expression of Ku70/80 is associated with CHEK2 germline mutations in breast cancer.

    Jakub, Rosik / Filip, Machaj / Daniel, Bodnar / Jolanta, Hybiak / Tomasz, Huzarski / Cezary, Cybulski / Jan, Lubiński / Wenancjusz, Domagała / Domagała, Paweł

    Polish journal of pathology : official journal of the Polish Society of Pathologists

    2023  Volume 74, Issue 2, Page(s) 75–81

    Abstract: Ku70/80 protein inhibitors reduce the repair of DNA double-strand breaks via the Ku70/80 pathway, so they can be used to treat cancers with Ku70/80 overexpression. Since the association of Ku70/80 with germline CHEK2 mutations in breast cancer is unknown, ...

    Abstract Ku70/80 protein inhibitors reduce the repair of DNA double-strand breaks via the Ku70/80 pathway, so they can be used to treat cancers with Ku70/80 overexpression. Since the association of Ku70/80 with germline CHEK2 mutations in breast cancer is unknown, in this study we evaluated the expression of Ku70/80 in breast cancers with germline CHEK2 mutations. Immunohistochemistry with a Ku70/80 antibody on tissue microarrays from 225 CHEK2-associated breast cancers was used and automatically assessed with computerized image analysis. We report that the vast majority of breast cancers expressed high level of nuclear Ku70/80 and a small percentage of tumors (3.5%) were negative for Ku70/80 expression. There was a significant difference between the nuclear Ku70/80 expression in CHEK2-associated vs. CHEK2-non-associated breast cancers in all tumors (p = 0.009), and in the estrogen receptor (ER) positive subgroup of breast cancers (p = 0.03). This study is the first reporting an association of Ku70/80 expression with CHEK2 germline mutations in breast cancer. The results suggest that evaluation of Ku70/80 expression in breast cancer may improve the selection of breast cancer patients for Ku70/80 inhibitor therapy, and point to CHEK2-associated breast cancer and a subset of ER-positive breast cancer as potential suitable targets for such therapy.
    MeSH term(s) Female ; Humans ; Breast Neoplasms/genetics ; Checkpoint Kinase 2/genetics ; Germ-Line Mutation ; Image Processing, Computer-Assisted
    Chemical Substances Checkpoint Kinase 2 (EC 2.7.1.11) ; CHEK2 protein, human (EC 2.7.11.1) ; XRCC5 protein, human (EC 3.6.4.12) ; Xrcc6 protein, human (EC 3.6.4.12)
    Language English
    Publishing date 2023-09-20
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 1283064-1
    ISSN 1233-9687 ; 0031-3114
    ISSN 1233-9687 ; 0031-3114
    DOI 10.5114/pjp.2023.129518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 377: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Genetic testing for hereditary breast cancer in Poland: 1998-2022.

    Gronwald, Jacek / Cybulski, Cezary / Huzarski, Tomasz / Jakubowska, Anna / Debniak, Tadeusz / Lener, Marcin / Narod, Steven A / Lubinski, Jan

    Hereditary cancer in clinical practice

    2023  Volume 21, Issue 1, Page(s) 9

    Abstract: BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of ... ...

    Abstract BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of three founder mutations. A rapid inexpensive test for these three mutations can be used to screen all Polish adults at a reasonable cost. In the region of Pomerania of North-western Poland nearly half a million tests have been performed, in large part through engaging family doctors and providing ready access to testing through the Pomeranian Medical University. The following commentary provides a history of genetic testing for cancer in Pomerania and the current approach to facilitating access to genetic testing at the Cancer Family Clinic for all adults living in the region.
    Language English
    Publishing date 2023-06-13
    Publishing country Poland
    Document type Letter
    ZDB-ID 2252512-9
    ISSN 1897-4287 ; 1731-2302
    ISSN (online) 1897-4287
    ISSN 1731-2302
    DOI 10.1186/s13053-023-00252-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6407: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update.

    Savanevich, Alena / Ashuryk, Olgierd / Cybulski, Cezary / Lubiński, Jan / Gronwald, Jacek

    Hereditary cancer in clinical practice

    2021  Volume 19, Issue 1, Page(s) 13

    Abstract: Background: Mutations in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Central-Eastern European counties, the founder mutations in the BRCA1 are responsible for a significant proportion of ovarian cancer cases, ... ...

    Abstract Background: Mutations in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Central-Eastern European counties, the founder mutations in the BRCA1 are responsible for a significant proportion of ovarian cancer cases, however, regional differences in the frequencies of various mutations may exist. The spectrum and frequency of BRCA1/2 mutations between ovarian cancer patients have not yet been precisely established in Belarus.
    Methods: Two hundred fourteen consecutive unselected cases of ovarian cancer patients from the region of West Belarus were examined. We studied 13 founder mutations in BRCA1 (c.5266dupC, c.4035delA, c.5251C > T, c.181 T > G, c.676delT, c.68_69delAG, c.3700_3704delGTAAA, c.1687C > T, c.3756_3759delGTCT) and in BRCA2 (c.658_659delGT, c.7913_7917delTTCCT, c.3847_3848delGT, c.5946delT) characteristic for Central European population.
    Results: A BRCA1 or BRCA2 founder mutations were detected in 54 of the 214 (25.2%) ovarian cancer cases. The BRCA1 c.5266dupC mutation was detected in 28 patients, followed by c.4035delA mutation observed in 18 patients. BRCA1 c.3756_3759delGTCT, c.68_69delAG, and c.1687C > T were found in 3, 2, and 1 women, respectively. BRCA2 c.658_659delGT mutation was detected in 2 ovarian cancer patients. The median age of diagnosis of the 54 hereditary ovarian cancers was 57.5 years.
    Conclusions: The frequency of 13 causative BRCA1 and BRCA2 founder mutations in West Belarus was higher than in other Slavic countries. Testing of BRCA1 (c.5266dupC, c.4035delA, c.3756_3759delGTCT, c.68_69delAG, c.1687C > T as well as c.181 T > G) and BRCA2 (c.658_659delGT) mutations should be considered an inexpensive and sensitive test panel for this population.
    Language English
    Publishing date 2021-01-21
    Publishing country Poland
    Document type Journal Article
    ZDB-ID 2252512-9
    ISSN 1897-4287 ; 1731-2302
    ISSN (online) 1897-4287
    ISSN 1731-2302
    DOI 10.1186/s13053-021-00169-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6407: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Serum Levels of Copper and Zinc and Survival in Breast Cancer Patients.

    Szwiec, Marek / Marciniak, Wojciech / Derkacz, Róża / Huzarski, Tomasz / Gronwald, Jacek / Cybulski, Cezary / Dębniak, Tadeusz / Jakubowska, Anna / Lener, Marcin R / Falco, Michał / Kładny, Józef / Baszuk, Piotr / Kotsopoulos, Joanne / Narod, Steven A / Lubiński, Jan

    Nutrients

    2024  Volume 16, Issue 7

    Abstract: There is emerging interest in the relationship between several serum micronutrients and the prognosis of patients with breast cancer. The relationship between serum zinc and copper levels and breast cancer prognosis is unclear. In our study, we included ... ...

    Abstract There is emerging interest in the relationship between several serum micronutrients and the prognosis of patients with breast cancer. The relationship between serum zinc and copper levels and breast cancer prognosis is unclear. In our study, we included 583 patients with breast cancer diagnosed between 2008 and 2015 in the region of Szczecin, Poland. In a blood sample obtained before treatment, serum zinc and copper levels were quantified by mass spectroscopy. Each patient was assigned to one of four categories (quartiles) based on the distribution of the elements in the entire cohort. Patients were followed from diagnosis to death over a mean of 10.0 years. The 10-year overall survival was 58.3% for women in the highest and 82.1% for those in the lowest quartile of serum copper/zinc ratio (
    MeSH term(s) Humans ; Female ; Breast Neoplasms ; Copper ; Zinc ; Breast ; Mass Spectrometry
    Chemical Substances Copper (789U1901C5) ; Zinc (J41CSQ7QDS)
    Language English
    Publishing date 2024-03-29
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu16071000
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: CHEK2 Alleles Predispose to Renal Cancer in Poland.

    Zlowocka-Perlowska, Elzbieta / Narod, Steven A / Cybulski, Cezary

    JAMA oncology

    2019  Volume 5, Issue 4, Page(s) 576

    MeSH term(s) Alleles ; Carcinoma, Renal Cell ; Checkpoint Kinase 2/genetics ; Germ-Line Mutation ; Humans ; Kidney Neoplasms ; Poland ; Prevalence
    Chemical Substances Checkpoint Kinase 2 (EC 2.7.1.11) ; CHEK2 protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2019-02-28
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2019.0022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.

    Narod, Steven / Sopik, Victoria / Cybulski, Cezary

    JAMA oncology

    2018  Volume 4, Issue 7, Page(s) 1012

    MeSH term(s) Alleles ; BRCA1 Protein ; BRCA2 Protein/genetics ; Breast Neoplasms/genetics ; Female ; Genetic Predisposition to Disease ; Humans ; Jews ; Mutation
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human
    Language English
    Publishing date 2018-07-02
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2018.0595
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients.

    Pietrzak, Sandra / Marciniak, Wojciech / Derkacz, Róża / Matuszczak, Milena / Kiljańczyk, Adam / Baszuk, Piotr / Bryśkiewicz, Marta / Sikorski, Andrzej / Gronwald, Jacek / Słojewski, Marcin / Cybulski, Cezary / Gołąb, Adam / Huzarski, Tomasz / Dębniak, Tadeusz / Lener, Marcin R / Jakubowska, Anna / Kluz, Tomasz / Scott, Rodney J / Lubiński, Jan

    Nutrients

    2024  Volume 16, Issue 4

    Abstract: The most prevalent type of cancer among males is prostate cancer. Survival is considered quite good, but it can be further improved when risk factors are optimized. One of these factors is micronutrients, including Se and Zn. To our knowledge, the ... ...

    Abstract The most prevalent type of cancer among males is prostate cancer. Survival is considered quite good, but it can be further improved when risk factors are optimized. One of these factors is micronutrients, including Se and Zn. To our knowledge, the interaction between Se and Zn and prostate cancer remains undescribed. This study aimed to investigate the optimal levels of selenium (Se) and zinc (Zn) and their impact on the survival of individuals diagnosed with prostate cancer. A total of 338 prostate cancer patients were enrolled in this study, which was conducted in Poland between 2009 and 2015. Mass spectrometry, which uses inductively coupled plasma mass, was used to assess serum element levels before treatment. The study participants were categorized into quartiles (QI-QIV) based on the distributions of Se and Zn levels observed among surviving participants. Cox regression was used to assess the association between serum Se and Zn levels and the survival of prostate cancer patients. Our results reveal the effect of combined Se and Zn levels on survival in prostate cancer patients (SeQI-ZnQI vs. SeQIV-ZnQIV; HR = 20.9). These results need further research to establish Se/Zn norms for different populations.
    MeSH term(s) Male ; Humans ; Selenium ; Zinc ; Prostatic Neoplasms ; Micronutrients/analysis ; Mass Spectrometry/methods ; Copper
    Chemical Substances Selenium (H6241UJ22B) ; Zinc (J41CSQ7QDS) ; Micronutrients ; Copper (789U1901C5)
    Language English
    Publishing date 2024-02-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu16040527
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: RECQL: a DNA helicase in breast cancer.

    Akbari, Mohammad R / Cybulski, Cezary

    Oncotarget

    2015  Volume 6, Issue 29, Page(s) 26558–26559

    MeSH term(s) Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Cell Line, Tumor ; Female ; Founder Effect ; Genetic Predisposition to Disease ; Humans ; Mutation ; Mutation, Missense ; Poland ; Quebec ; RecQ Helicases/genetics
    Chemical Substances RECQL protein, human (EC 3.6.1.-) ; RecQ Helicases (EC 3.6.4.12)
    Language English
    Publishing date 2015-09-29
    Publishing country United States
    Document type Editorial
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.5452
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top